Related to RainDance Forges Separate Pacts with Ambry and Roche to Advance ADME Analysis

• Roche Hands Phase IIb-Stage HPV Vaccine Back To Transgene
  
• FDA Grants 510(k) Approval to OraSure and Roche for Drug-of-Abuse Assays
  
• CDI to Supply iPSC-Derived Human Heart Cells for Roche's Drug Development Efforts
  
• Invida to Market Roche’s Primary Care Portfolio in Korea
  
• Ambry Genetics Certified as Ion Torrent’s First Authorized Sequencing Service Provider
  
• Ambry Genetics to Provide Entire Roche NimbleGen Array Portfolio
  
• AgenoLAB Becomes First German Lab to Purchase Roche’s RTCA Cardio Instrument
  
• Plexxikon and Roche Report Positive Data from Phase III BRAF Mutation Melanoma Study
  
• Merck & Co. Teams with Roche to Develop Companion Diagnostics for Cancer Therapy
  
• Roche to Supply UCLA Centers with Technologies and Support for Biomarker Discovery
  
• Nycomed to Market Roche’s Osteoporosis Treatment in Asia Pacific
  
• Pivotal Study Results Lead Genentech to Project Vismodegib Filing in U.S. During 2011
  
• Merck & Co. and Roche Go Global with Marketing for Victrelis in HCV
  
• PerkinElmer to Take Over Distribution of NimbleGen CGX Cytogenetics Array Workflow from Roche
  
• Roche Pays Evotec $10M Up Front in Deal to Develop MAO-B Inhibitor for Alzheimer Disease
  
• Roche Establishes Links with Swedish Academic Innovation Initiative
  
• Roche Gives Arrowhead RNAi Assets and Facility in Madison, WI
  
• Roche and Aileron Pin Third Program to Stapled Peptide Drug Collaboration
  
• BC Cancer Agency Buys RainDance’s ThunderStorm High-Throughput Sequencing System
  
• Roche Nabs PTC’s SMA Program for $30M Up Front